Western Australia has announced that they will roll out a statewide program for long-acting monoclonal antibody Nirsevimab from April 2024. Nirsevimab (available in Australia under the brand name Beyfortus) is indicated for the prevention of respiratory syncytial virus (RSV) disease in neonates and infants.  

Western Australian children eligible for Nirsevimab include: 

  • all infants from birth to under 8 months 
  • infants from 8 months to 19 months at increased risk of severe RSV. 

Nirsevimab will be available at birthing hospitals, GP practices, community health clinics and at Aboriginal Medical Services across Western Australia. 

There were approximately 128,000 confirmed RSV cases in Australia in 2023, including approximately 65,000 children aged 4 years and under. 

For more information, see MVEC: RSVWA Media Statement on RSV